Inhibition of the activity of poly (ADP-ribose) polymerase in ischemia-reperfusion injury.
Thiemermann
C
C
D000818:Animals; D004249:DNA Damage; D015195:Drug Design; D004734:Energy Metabolism; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D005246:Feedback; D006801:Humans; D007511:Ischemia / Q000188:drug therapy / Q000201:enzymology*; D009203:Myocardial Infarction / Q000188:drug therapy; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000517:prevention & control; D009243:NAD / Q000378:metabolism; D009536:Niacinamide / Q000502:physiology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000502:physiology; D015427:Reperfusion Injury / Q000201:enzymology* / Q000517:prevention & control; D012995:Solubility
D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D009243:NAD; D009536:Niacinamide; D011065:Poly(ADP-ribose) Polymerases